buprenorphine extended-release Sublocade
Selected indexed studies
- Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. (JAMA Netw Open, 2024) [PMID:38976265]
- Buprenorphine Extended-Release Injection for Subcutaneous Use (Sublocade(®)): An Overview for Psychiatric Advanced Practice Nurses. (J Psychosoc Nurs Ment Health Serv, 2025) [PMID:40626798]
- Perioperative Management of Extended-release Buprenorphine. (J Addict Med, 2023) [PMID:35862898]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. (2018) pubmed
- Buprenorphine Extended-Release Injection for Subcutaneous Use (Sublocade(®)): An Overview for Psychiatric Advanced Practice Nurses. (2025) pubmed
- Subcutaneous Extended-Release Buprenorphine Use in Pregnancy. (2020) pubmed
- Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial. (2024) pubmed
- Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. (2024) pubmed
- Perioperative Management of Extended-release Buprenorphine. (2023) pubmed
- Extended-release monthly buprenorphine injection. (2023) pubmed
- Perioperative Management of Extended-Release Buprenorphine: A Narrative Review and Case Series. (2023) pubmed
- Extended-release buprenorphine in pregnancy. (2024) pubmed
- Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. (2023) pubmed